Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Reid

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
Neurology and Therapy|January 10, 2026
Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK TrialJerry R Mendell, Francesco Muntoni, Craig M McDonald, et al.
Nature Medicine|October 9, 2024
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trialJerry R Mendell, Francesco Muntoni, Craig M McDonald, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
Neurology and Therapy|January 10, 2026
Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK TrialJerry R Mendell, Francesco Muntoni, Craig M McDonald, et al.
Nature Medicine|October 9, 2024
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trialJerry R Mendell, Francesco Muntoni, Craig M McDonald, et al.
Pageof 5